Coeptis Therapeutics Holdings, Inc. (COEP)
Apr 24, 2026 - COEP merged into ZSQR
16.40
+0.19 (1.17%)
Inactive · Last trade price
on Apr 24, 2026
COEP Revenue
In the year 2025, Coeptis Therapeutics Holdings had annual revenue of $1.36M. Coeptis Therapeutics Holdings had revenue of $862.05K in the quarter ending December 31, 2025.
Revenue (ttm)
$1.36M
Revenue Growth
n/a
P/S Ratio
74.88
Revenue / Employee
$227,174
Employees
6
Market Cap
102.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCOEP News
- 4 days ago - Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market - PRNewsWire
- 21 days ago - Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application - GlobeNewsWire
- 2 months ago - Coeptis Receives Shareholder Approval Towards Z Squared Merger - GlobeNewsWire
- 4 months ago - Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared - GlobeNewsWire
- 7 months ago - Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating - GlobeNewsWire
- 10 months ago - Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd - GlobeNewsWire
- 10 months ago - Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared - GlobeNewsWire
- 11 months ago - Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology - GlobeNewsWire